Dr Andres Roman-Urrestarazu University positionDirector of Studies PBS Trinity Hall DepartmentsDepartment of Public Health and Primary Care InstitutesHome pagehttp://www-bmu.psychiatry.cam.ac.uk/people/... Research ThemesInterestsMy research interests are related to developmental disorders such as Autism, Schizophrenia and ADHD. I am interested in risk factors and traits that predispose to neuro-developmental disorders.  Regression Analysis of Grey Matter Volume and Grooved Pegboard Scores Click image to view full-size Research Focus
EquipmentBehavioural analysis Cross-sectional and cohort studies Longitudinal Studies Magnetic resonance imaging (MRI) Neuropsychological testing Collaborators
Associated News ItemsKey publicationsRoman-Urrestarazu A, Lindholm P, Moilanen I, Kiviniemi V, Miettunen J, Jääskeläinen E, Mäki P, Hurtig T, Ebeling H, Barnett JH, Nikkinen J, Suckling J, Jones PB, Veijola J, Murray GK. (2015), “Brain structural deficits and working memory fMRI dysfunction in young adults who were diagnosed with ADHD in adolescence.” Eur Child Adolesc Psychiatry 2015 Aug 26. Andres Roman-Urrestarazu, Graham K Murray, Anna Barnes, Jouko Miettunen, Erika Jääskeläinen, Pirjo Mäki, Juha Nikkinen, Jukka Remes, Sari Mukkala, Jenni Koivukangas, Markus Heinimaa, Irma Moilanen, John Suckling, Vesa Kiviniemi, Peter B Jones, Juha Veijola (2014), “Brain structure in different psychosis risk groups in the Northern Finland 1986 birth cohort.” Schizophr. Res. Mar 24;153(1-3):143-9 Publications2016Roman-Urrestarazu A, Corazza O (2016), “Psychoactive substances bill: written evidence submitted by Dr Ornella Corazza and Dr Andres Roman Urrestarazu” The Psychoactive Substance Bill 2015-16 http://www.publications.parliament.uk/pa/cm201516/cmpublic/psychoactive/memo/psb17.htm 2015Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li JH, Yu WJ, Kapitány-Fövény M, Farkas J, Di Giannantonio M, Corazza O. (2015), “Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.” Biomed Res Int 2015:968786. doi: 10.1155/2015/968786. Epub 2015 Nov 10 in pressThomson S., Mossialos E. and Evans R. G. (eds) (in press), “Private health insurance: history, politics, performance” Cambridge University Press. 2011Roman-Urrestarazu, Andres; Murray, Graham K.; Barnes, Anna; Miettunen, Jouko; Jääskeläinen, Erika; Nikkinen; Remes, Jukka; Starck, Tuomo; Moilanen, Irma; Mäki, Pirjo; Suckling, John; Kiviniemi, Vesa; Jones, Peter B.; Veijola, Juha (2011), “Structural MRI in the 1986 Northern Finland Birth Cohort: findings among different psychosis risk profiles in a cross sectional study.” International Clinical Psychopharmacology Volume 26 - Issue - p e140– e141. 2009Technical Lead (2009), “Topotecan for the treatment of recurrent and stage IVB cervical cancer. NICE technology appraisal guidance 183, Technical Lead. Published October 2009 ” http://guidance.nice.org.uk/TA183/Guidance/pdf/English. Technical Lead (2009), “Pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE technology appraisal guidance 181” http://guidance.nice.org.uk/TA181/Guidance/pdf/English |